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Fast identification of the antibacterial  
in Aspergillus species
Abstract:
Background and Purpose: Aspergillus genus biosynthesize a large 
number of metabolites with wide-ranging bioactivities, but how to target 
the active compounds quickly and accurately? In this work, we provide a 
strategy to fast identify bioactive metabolites in fungi with similar morphol-
ogy but different antimicrobial activities.
Materials and Methods: Combined with High Performance Liquid 
Chromatography (HPLC) profiles and bioactivity screening of fungal ex-
tracts, three Aspergillus sp. strains YSN038, YSN052 and YSN064 were 
studied. The bacteria Bacillus pumilus, Bacillus subtilis, Staphylococcus 
aureus, Kocuria rhizophila, Escherichia coli and Ralstonia solanacearum 
were used for antibiotic assay.
Results: Three strains showed the similar morphology, but the crude 
extracts of YSN038 and YSN064 displayed antibacterial activities against 
B. pumilus, B. subtilis, S. aureus and K. rhizophila, whereas YSN052 had 
not. The compound contributed to antibacterial activity in vitro was rap-
idly identified, isolated and characterized. Compound 3 connected with 
specific HPLC peak should be the antibiotic substance by analysis of HPLC 
profiles, and was confirmed after the following antimicrobial tests. The 
compound was elucidated as butyrolactone I based on nuclear magnetic 
resonance(NMR) and mass spectrometry (MS) data, and showed various 
biological activities.
Conclusions: Our study has significant scope on targeting antibacterial 
metabolites. The described method could also be used as a rapid and cost-
effective tool for screening other bioactivity products. As such, this article 
could offer a fast approach to isolate drug-lead compounds from microorgan-
isms.
IntroductIon
Aspergillus genus is well known for its medical and commercial im-portance (1). They are prolific producers of lifesaving drugs, dev-
astating toxins, or mass produced industrial enzymes (2). Many clini-
cally beneficial secondary metabolites are produced by Aspergillus 
genus, such as lovastatin, terrein, griseofulvin. Lovastatin, also known 
as mevinolin or monacolin K, is effective clinical drug used for reduc-
ing serum cholesterol and slowing the progression of atherosclerosis. 
Lovastatin and its related compounds inhibit cholesterol synthesis by 
inhibiting the rate-limiting step in cellular cholesterol biosynthesis (3). 
Terrein, one of Aspergillus major secondary metabolites has ecological, 
antimicrobial, antiproliferative and antioxidative activities (4). Some 
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chemical with many uses in the food, beverage and 
other industries (5).
Aspergillus genomes contain a large number of second-
ary metabolite biosynthetic genes. However, only a few 
products can be actually determined. For example, there 
are 33-79 putative polyketide synthase (PKS) and non-
ribosomal peptide (NRPS) encoding genes in sequenced 
Aspergillus genomes and only 9%-30% of these genes can 
connect with their products (3). This information reveals 
that many compounds in Aspergillus species are waiting 
for discovery.
The traditional chemical analysis of fungal secondary 
metabolite is a time-consuming and labour-consuming 
process. First, a large number of strains are isolated, then 
the secondary metabolites produced by those strains are 
evaluated by bioassay, last, the strain with biologically 
activity is large-scale fermented, and every compound of 
the crude extraction of the fermentation is purified for 
screening activated compound. This method cannot tar-
get the activated compound rapidly and accurately, and 
it is imperative to find a method that could detect valuable 
compound from microorganism rapidly and accurately.
Herein, we described a fast antibacterial identification 
strategy. To screen the antimicrobial metabolites against 
Bacillus pumilus, Bacillus subtilis, Staphylococcus aureus, 
Kocuria rhizophila, Escherichia coli, and Ralstonia sola-
nacearum, three Aspergillus strains YSN038, YSN052 and 
YSN064 with similar morphology but different antibacte-
rial activity were investigated. By comparing the HPLC 
profiles and appropriate antibiotic activities of the crude 
extracts, the activated compound was identified directly. 
This study provides a method to fast identify bioactive 
metabolites in the similar microbial genus.
MAtErIALS And MEtHodS
Strains and culture conditions
YSN038, YSN052 and YSN064 were maintained on 
potato dextrose agar (PDA) plates containing 0.3% po-
tato extract, 2% glucose, and 1.5% agar. Freshly inocu-
lated plates were incubated at 30°C for 10 days. The test 
bacteria used in this study were Bacillus pumilus (CGMCC 
1.3533), Bacillus subtilis (ATCC 10626), Staphylococcus 
aureus (ATCC 25923), Kocuria rhizophila (CGMCC 
1.2156), Escherichia coli (MG1655), and Ralstonia sola-
nacearum (ACCC 11608) stocked in our lab. B. subtilis, 
S. aureus and E. coli were grown on LB medium at 37°, 
B. pumilus, K. rhizophila and R. solanacearum were grown 
on NA medium at 30°.
Analysis of 18S rdnA
The genomic DNA of YSN038, YSN052 and YSN064 
were extracted from three to five days PDA plates by Phe-
nol: chloroform: isopentanol, precipitated with ethanol, 
and resuspended in TE buffer (6). The quantity of DNA 
was measured by Thermo Scientific Nano Drop spectro-
photometer. The sequences of consensus primers used for 
the PCR amplification of 18S rDNA fragment were ITS4 
(TCCTCCGCTTATTGATATGC) and ITS5 
(GGAAGTAAAAGTCGTAACAAGG). Phylogenetic 
tree was constructed using the Neighbor joining method 
with bootstrapping 500 times by MEGA 6.0. The partial 
18S rDNA nucleotide sequences of YSN038, YSN052, 
and YSN064 has been submitted to GenBank under ac-
cession number KT375566, KT375567 and KT375568.
Extraction and isolation
Agar surface culture fermentations were done by grow-
ing YSN038, YSN052 and YSN064 on 20 PDA plates for 
10 days, then they were extracted with methanol in 1:2 
(v/v) for three times. The crude extracts were obtained 
after removal of the organic solvent by the rotary evapora-
tor. The extracts were weighed and preserved in sterile 
bottles at 4°.
Crude Extractions were analyzed by reversed phase 
HPLC on a Shimadzu DGU-20A5R equipped with a 
Kromasil C18 column (100-5-C18). HPLC conditions for 
the analysis of crude extracts were a linear 30−80% gradi-
ent of CH3OH in H2O over 8 min, 80% CH3OH in 
H2O for 10 min, a linear 80−95% gradient of CH3OH 
in H2O over 1 min, 95% CH3OH in H2O for 5 min, a 
linear 95−30% gradient of CH3OH in H2O over 1 min, 
and 30% CH3OH in H2O for 3 min; flow rate of 0.8 ml/
min; detection at 280 nm. Scaled-up cultivation of fungi 
strains for 50 plates, and isolated of compounds through 
ODS column chromatography (YMC, 40 μm), silica gel 
chromatography (Merck, 40 μm) and semi-preparative 
HPLC (Waters, Delta Prep 4000, 10 × 250 mm). 1H 
NMR, 13C NMR and heteronuclear multiple-bond cor-
relation spectroscopy (HMBC) spectra were recorded in 
dimethyl sulfoxide (DMSO) solution on a Bruker AV-500 
instrument at 500 MHz for 1H NMR and 125MHz for 
13C NMR. The chemical shift values (°) were given in 
parts per million (ppm), and the coupling constants were 
given in hertz. High resolution electrospray ionization 
mass spectrometry (ESIMS) were obtained with an Agi-
lent 1100 series LC/MSD ion trap mass spectrometer. MS 
analysis was performed in positive mode using full scan 
mode. The conditions of the ESI source were as follows: 
capillary voltage, 3.0 kV; drying gas (N2) flow rate, 6.0 L/
min, temperature, 330°; nebulizing gas (N2) pressure, 40 
psi; flow rate, 0.3 ml/min.
Antimicrobial activity assays
The antimicrobial activity was screened by the method 
of disk diffusion. The crude extracts were prepared in 
methanol. The amount of crude extracts was adjusted to 
80 μg on a 7 mm filter paper disk. The completely dried 
disks with crude extract were attached to the plates 
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lawned with 200 ml test bacteria. The plates were labeled 
and incubated at 30° (B. pumilus, K. rhizophila and R. 
solanacearum) or 37° (B. subtilis, S. aureus and E. coli) for 
18 to 24 h. After incubation, clear zones of inhibition 
around the disks indicated the sensitivity rate of the test 
bacteria to each extract and diameters of the clear zones 
were taken as index of the degree of sensitivity. Tests were 
carried out in three times. Disk without any crude extract 
was used as negative control, and kanamycin as positive 
control. The inhibitory zones of extracts were expressed 
as the mean ± standard deviation (7).
Microdilution method using 96-well microplate was 
performed to quantify the antimicrobial activity of com-
pound 3. The stock solution was made by dissolving 200 
μg compound 3 in 1 ml methanol. 10 μl of compound 3 
solution (200 μg/ml) was added into the second row of 
microplate, two-fold dilutions of compound 3 (200-0.39 
μg/ml) was made by dispensing the solutions into the 3-11 
wells. 100 μl of medium was added into the first row as 
the BLANK and 10 μl of methanol was added into the 
last row as the control. 90 μl of test strain suspension 
inoculated into all the wells except the first row. The plates 
were tested after incubated at 30° or 37° for 18 to 24 h. 
Results were registered in an ELISA reader, and IC50 were 
calculated graphically from concentration-inhibition 
curves (8).
rESuLtS
Phylogenetic analysis of fungal strains
The genomic DNAs of YSN038, YSN052 and YSN064 
were extracted, and 18S rDNA fragments were amplified 
using universal primers ITS4 and ITS5. The alignment 
of 18S rDNA showed that three strains had high identity 
with Aspergillus genus at the range of 96.8% to 99.8%. 
These 18S rDNA sequences had high identity with Asper-
gillus neoafricanus RRL 2399 and Aspergillus terreus 
DF12079 particularly, so these fungal strains were de-
fined as Aspergillus sp.YSN038, Aspergillus sp.YSN052, 
and Aspergillus sp. YSN064 (Table 1). Phylogenetic tree 
was shown in Figure 1 below.
three fungal strains displayed different 
antimicrobial activity
Three strains showed similar morphology, they were 
pale brown or brown, and get darker, dense texture, flat 
or with radial grooves on PDA plate after aging. In some 
cases, they were able to become floccose.
20 PDA plates grown on YSN038, YSN052 and 
YSN064 were successively extracted with methanol to 
afford the crude extracts (0.31 g, 0.25 g and 0.26 g on 
YSN038, YSN052, YSN064). Disk diffusion method was 
performed to test antimicrobial activity against B. pumi-
lus, B. subtilis, S. aureus, K. rhizophila, E. coli and R. so-
lanacearum. Positive results were observed with 80 μg/
disk crude extracts of YSN038 and YSN064 on B. pumi-
lus, B. subtilis, S. aureus, and K. rhizophila, but no effect 
on E. coli and R. solanacearum. The inhibitory zones were 
shown below. The crude extract of YSN052 displayed no 
effect on all the test bacteria (Table 2 and Figure 2).
A: HPLC profiles of crude extracts of YSN038, 
YSN052 and YSN064. 2 and 4 have no antibacterial ac-
tivities. 3 has antibacterial activity. B: Crude extracts of 
YSN038 and YSN064, but not YSN052, can inhibit the 
growth of B. pumilus, B. subtilis, S. aureus, and K. rhi-
zophila.
Identification antibacterial activities 
and structures of the compounds
YSN038, YSN052 and YSN064 displayed different 
antibacterial activities to the test bacteria implied that 
they produced different secondary metabolites. HPLC 
profiles showed that the crude extracts of YSN038, 
YSN052 and YSN064 had four main peaks of 1, 2, 3, 4, 
two main peaks of 2, 4, and three main peaks of 2, 3, 4 
respectively. YSN052 could not inhibit the growth of B. 
pumilus, B. subtilis, S. aureus, and K. rhizophila, indicated 
that peaks 2 and 4 have no contribution to antibacterial 
activity, which means peaks 1 and/or 3 in YSN038, and 
peak 3 in YSN064 should had antibacterial ability. 
YSN064 with peaks 2, 3 and 4 exhibited antibacterial 
activities, implied that peak 3 should have the antibiotic 
Figure 1: Phylogenetic tree of YSN038, YSN052, YSN064 and 
other Aspergillus species group
Table 1: Identity between YSN038, YSN052, YSN064 and other 
Aspergillus genus
YSN038 YSN052 YSN064
Aspergillus terreus DF12079 99.5% 99.7% 99.7%
Aspergillus candidus CY104 96.8% 97.0% 97.0%
Aspergillus alabamensis NRRL 29810 99.2% 99.4% 99.4%
Aspergillus flavus TUHT153 97.0% 97.3% 97.3%
Aspergillus neoafricanus RRL 2399 99.8% 99.8% 99.8%
Aspergillus ochraceus MP2 97.6% 97.4% 97.4%
Aspergillus pseudoterreus CICC2690 99.1% 99.1% 99.1%
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activity (Figure 1). Also we were not sure if compound 1 
in YSN038 had activity.
In order to confirming the compounds’ antibacterial 
activities and structures, 50 PDA plates grown with 
YSN038 were extracted with methanol to gather 1.8 g 
crude extracts. The crude extract was subjected to ODS 
column chromatography and eluted with MeOH and 
H2O (Fraction A, H2O, 100 ml; Fraction B, 50/50, 100 
ml; Fraction C, 55/45, 100 ml; Fraction D, 60/40, 100 ml; 
Fraction E, 65/35, 100 ml; Fraction F, MeOH, 100 ml; 
v/v). Compound 1 (7.0 mg, retention time: 17.5 min) and 
compound 2 (7.0 mg, retention time: 17.5 min) were pu-
rified from fraction B by reversed phase HPLC (MeOH/
H2O = 45/55, v/v). Compound 3 (7.9 mg) was obtained 
from fraction C through reversed phase HPLC (MeOH/
H2O = 55/45, v/v, 20 min) and Silica gel column chroma-
tography eluted with hexane/ethyl acetate mixture solvent 
(1/1, v/v). Compound 4 (5.3 mg) was prepared by reversed 
phase HPLC (MeOH/H2O = 55/45, v/v, 25 min).
The antibacterial activity confirmed by disk diffusion 
method. Compound 3 showed same bioactivity as that of 
crude extraction, but compound 1 had no bioactivity(table 
3). IC50 of compound 3 were determined and were from 
15.6 μg/ml to 62.3 μg/ml to B. pumilus, B. subtilis, S. 
aureus and K. rhizophila seperatively (table 3). Compound 
3 had no inhibitory activity to E. coli and R. solanacearum 
with the concentration of 0.39-200 μg/ml.
The molecular formula of 3 was determined as 
C24H24O7 by high-resolution electrospray ionization mass 
spectrometry (HRESIMS), which gave a quasi-molecular 
ion peak at m/z: 425.1647 (calcd for C24H25O7 [M+H]
+, 
425.1596). The 1H NMR spectrum showed a set of four 
ortho-coupled aromatic hydrogens at d 7.50 (d, 2H, J = 
8.8 Hz) and 6.87 (d, 2H, J = 8.8 Hz), suggesting a 1, 
4-substituted aromatic ring. Other three aromatic hydro-
gens at d 6.53 (d, 1H, J = 6.8 Hz), 6.47 (dd, 1H, J1 = 6.8 
Hz, J2 = 2.4 Hz), and 6.36 (d, 1H, J = 2.4 Hz), indicating 
a 1, 3, 5- substituted aromatic ring. And hydrogens signals 
at d 1.53 (s, 3H, -CH3), 1.62 (s, 3H, -CH3), 2.99 (d, 2H, 
J = 6.8 Hz, -CH2-), and a olefinic proton at 5.01 (m, 1H) 
indicated existing a isopentene group. In 13C NMR spec-
trum showed 24 carbon signals, and the signals of d 127.3 
(C-7), 138.1 (C-8), 168.0 (C-9) and 84.7 suggested a un-
saturated lactone grouop existing. The NMR spectrum 
were same to butyrolactone I(9), thus compound 3 was 
elucidated as butyrolactone I (Table 4 and Figure 3).
Table 2: Inhibitory zones of YSN038, YSN052, and YSN064 crude 
extracts (80 μg/disk)




B. pumilus 13.2±0.8 NA 13.1±0.3
B. subtilis 13±0.4 NA 15.3±0.4
S. aureus 11.2±0.2 NA 11.9±0.7
K. rhizophila 10.2±0.2 NA 13.2±0.2
E. coli NA NA NA
R. solanacearum NA NA NA
The inhibitory zones of extracts were expressed as the mean ± standard 
deviation.
NA=not active
Table 3: Inhibitory zones of compound 1, 3 (80 μg/disk) and IC50 
of compound 3 of YSN038
Bacteria for  
antibacterial test
Inhibitory zones(mm) IC50 (μg/ml)
compound 1 compound 3 compound 3
B. pumilus NA 17.2±0.3 15.6±0.2
B. subtilis NA 15.4±0.5 48.8±0.5
S. aureus NA 14.1±0.2 62.3±0.3
K. rhizophila NA 11±0.2 62.3±0.2
E. coli NA NA NA
R. solanacearum NA NA NA
The inhibitory zones of extracts were expressed as the mean ± standard 
deviation.
NA=not active
Figure 2: HPLC profiles and antibacterial activities of YSN038, 
YSN052 and YSN064 crude extracts Figure 3: Structure of compound 3
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dIScuSSIonS
Secondary metabolism is dispensable to normal me-
tabolism, it is widely variable in occurrence, and may have 
a readily apparent biological function or not. Under con-
ditions of nutrient limitation, such as deprivation of eas-
ily assimilated carbon, nitrogen, or phosphorus sources, 
the organism enters a period of slower growth, morpho-
logical alterations, and changes in metabolism known as 
secondary metabolism. Therefore, many secondary me-
tabolite products cannot be actually discovered even so 
many genes mined in genomes. Due to the growth condi-
tions and low abundance of the metabolites, the products 
of most secondary metabolite biosynthetic genes are still 
unknown. If we change growth conditions or do large 
scale fermentation, the metabolites not identified maybe 
detected using our strategy.
Butyrolactone I and related compounds were a class of 
important secondary metabolite in Aspergillus, which 
holds a core structure of 3-Phenyl-4-Benzyl-d-butyrolac-
tone, the chemical structure is d-oxo-d-(p-hydroxyphenyl)-
d-(p-hydroxy-m-3,3-dimethylallylbenzyl)-d-methoxycar-
bonyl-d-butyrolactone I (10). Butyrolactone I inhibits 
eukaryotic cyclin-dependent kinases, protein kinases that 
control cell cycle progression in all eukaryotes (10). Wang 
investigated butyrolactone I inhibits H1N1, the cell toxic-
ity is lower at the same time, shows that the compound 
might be a candidate for antiviral flu drug. The effects of 
butyrolactone I on the prevention of germinal vesicle 
breakdown, changes of microtubular structures, and de-
velopment of porcine and bovine oocytes was studied (11, 
12), but the inhibition effect is temporary and reversible 
(13). A large number of derivative of butyrolactone I (bu-
tyrolactone II–VII and its sulphuric acid derivatives) (9, 
14-16) also showed various biological activity, which high-
lights the value of these compounds. Isobutyrolactone II 
had evident antiviral activity towards HSV-1 with IC50 
values of 21.8 ± 0.8 μg/ml, and butyrolactone V had po-
tent antifouling activity with EC50 values of 22.1 ± 0.8 
μg/ml towards barnacle Balanus amphitrite larvae (17).
Aspergillus sp. YSN038,YSN052 and YSN064 display-
ing different inhibitory activities on B. pumilus, B. subti-
lis, S. aureus, K. rhizophila, E. coli and R. solanacearum 
provides an opportunity to quickly identify the antibacte-
rial compound. After comparison with HPLC profiles 
and antibacterial activities of three Aspergillus sp. strains, 
the antibacterial compound 3 was quickly targeted, and 
the antibacterial activity was confirmed too. In the course 
of fungal secondary metabolite study, the researchers 
found that even morphological similar, strains could also 
have different spectrum of secondary metabolites. We can 
take advantage of this difference to find the active sub-
stance. Our method provides a strategy to fast identify 
bioactive metabolites in Aspergillus genus, and our study 
has significant scope on targeting antimicrobial metabo-
lites and other activity compounds. This method also 
provides a useful tool for drug discovery.
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